research
A Blood Assay Traveled Across Two Liver-Cancer Populations
An AI fragmentome classifier was evaluated in Guatemala and Romania, where liver-cancer causes and patient backgrounds differ.
Summary
An AI fragmentome classifier was evaluated in Guatemala and Romania, where liver-cancer causes and patient backgrounds differ.
Johns Hopkins researchers evaluated a DELFI blood assay in 377 people with and without hepatocellular carcinoma in Guatemala and Romania. The fragmentome classifier retained performance across the distinct populations; combining it with alpha-fetoprotein, age and sex improved sensitivity, while a MethID method helped trace tissue origins. The international study is a validation step, not a completed prospective screening program.
Why it matters
An AI fragmentome classifier was evaluated in Guatemala and Romania, where liver-cancer causes and patient backgrounds differ.
Limits and context
- The international study is a validation step, not a completed prospective screening program.
Key claims
An AI fragmentome classifier was evaluated in Guatemala and Romania, where liver-cancer causes and patient backgrounds differ.
Qualification: The international study is a validation step, not a completed prospective screening program.
Evidence: source-2026-08-01-008
Sources
- Johns Hopkins Medicine via Newswise: DELFI liver-cancer assay validationJohns Hopkins Medicine via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.